Since DX/HA was approved by the Food and Drug Administration in 2001 as an acceptable tissue-augmenting substance for subureteral injection, endoscopic treatment has become increasingly popular for treating vesicoureteral reflux (VUR). However, most paediatric urologists still continue to recommend ureteral reimplantation as the treatment of choice in the management of grade V VUR. The purpose of this study was to prospectively evaluate the effectiveness of endoscopic subureteral injection of DX/HA in the treatment of grade V reflux.
Endoscopic treatment of primary grade V vesicoureteral refluxusing hyaluronic acid copolymer (DX/HA) / M. Hunziker; N. Mohanan; F. D’Asta; P. Puri. - In: PEDIATRIC SURGERY INTERNATIONAL. - ISSN 0179-0358. - STAMPA. - 26:(2010), pp. 977-979.
Endoscopic treatment of primary grade V vesicoureteral refluxusing hyaluronic acid copolymer (DX/HA)
D'ASTA, FEDERICA;
2010
Abstract
Since DX/HA was approved by the Food and Drug Administration in 2001 as an acceptable tissue-augmenting substance for subureteral injection, endoscopic treatment has become increasingly popular for treating vesicoureteral reflux (VUR). However, most paediatric urologists still continue to recommend ureteral reimplantation as the treatment of choice in the management of grade V VUR. The purpose of this study was to prospectively evaluate the effectiveness of endoscopic subureteral injection of DX/HA in the treatment of grade V reflux.
| File | Dimensione | Formato | |
|---|---|---|---|
|
endoscopic.pdf
Accesso chiuso
Tipologia:
Versione finale referata (Postprint, Accepted manuscript)
Licenza:
Tutti i diritti riservati
Dimensione
161.17 kB
Formato
Adobe PDF
|
161.17 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
